论文部分内容阅读
该文通过对 45例冠心病 (CHD)患者外周血循环内皮素 (ET)、前列环素 (PGI2 )代谢产物 6 -酮类固醇 -前列腺素F1a(6 -keto -PGF1a)和白细胞 (WBC)、嗜中性粒细胞 (PMN)的测定 ,以了解CHD患者内皮细胞 (EC)的损伤及功能变化 ,并悦宁定 (enalapril)治疗组与对照组比较。结果显示 :CHD患者ET、WBC、PMN明显高于正常 ;6 -keto -PGF1a则明显低于正常 ,均与病情严重程度相一致。通过enalapril治疗后 ,上述指标明显改善 ,提示 :enalapril对CHD患者血管内皮细胞 (VEC)损伤有较好的保护和治疗作用。
In this paper, 45 cases of coronary heart disease (CHD) patients with peripheral blood endothelin (ET), PGI2 metabolites 6 - keto steroid - prostaglandin F1a (6 - keto - PGF1a) and white blood cells (WBC) Neutrophils (PMN) were measured in order to understand the damage and function changes of endothelial cells (ECs) in patients with CHD. The enalapril treatment group was compared with the control group. The results showed: ET, WBC and PMN in CHD patients were significantly higher than those in normal controls; 6-keto-PGF1a was significantly lower than normal, which was consistent with the severity of the disease. After enalapril treatment, the above indicators were significantly improved, suggesting that: enalapril CHD patients with vascular endothelial cell (VEC) injury have a better protective and therapeutic effect.